MedTrace Logo

Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLC

NCT02037997 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2016-02-23

No results posted yet for this study

Summary

The purpose of this study is to evaluate and compare safety and effectiveness of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With EGFR - TKI Resistance of EGFR Mutations

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

docetaxel

docetaxel 75mg/m2 ivgtt D1

DRUG

pemetrexed

pemetrexed 500mg/m2 ivgtt D1

DRUG

Erlotinib

Erlotinib 150mg qd

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Chang J hua, PD · Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02037997 on ClinicalTrials.gov